pcsk9

Documents about pcsk9

• Sex Hormones and Blood PCSK9 Levels#883456ClinicalTrials.gov
• PCSK9 Inhibitors in the Progression of Aortic Stenosis#992024ClinicalTrials.gov
• Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis#901075ClinicalTrials.gov
• PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies#15491HAL (France)
• PCSK9 in vascular smooth muscle cells: biology, pathology, and inhibition to fight atherosclerosis#257724HAL (France)
• PCSK9 and inflammation: A review of experimental and clinical evidence#948268Repositorio de Universidad Autónoma de Chile.
• Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors#837275ClinicalTrials.gov
• Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?#274371HAL (France)
• Sequence Variations in <i>PCSK9,</i> Low LDL, and Protection against Coronary Heart Disease#400175OpenAlex
• COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients#810560ClinicalTrials.gov
• Very Early PCSK9 Inhibition for Acute Myocardial Infarction#896751ClinicalTrials.gov
• PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis#850065ClinicalTrials.gov
• The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile#895543ClinicalTrials.gov
• A Study of PCSK9 Inhibitor AK102 in Healthy Subjects#850756ClinicalTrials.gov
• Impact of a Structured Educational Intervention on Knowledge, Attitudes, and Prescribing Perceptions Regarding PCSK9 Inhibitors Among Healthcare Professionals in Saudi Arabia: A Pre-Post Interventional Study#427379HAL (France)
• Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis#322476HAL (France)
• PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells#424946IRIS
• Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke#414417ClinicalTrials.gov
• In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme#123431ClinicalTrials.gov
• Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects#261329ClinicalTrials.gov
• Exploring the Other Side of Medication: A Patient Interview Study on Anti-PCSK9 Monoclonal Antibodies.#288876NCBI PubMed Central
• Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis#834435ClinicalTrials.gov
• Combining mRNA display and photo-crosslinking to discover high-affinity photoreactive peptide probes for PCSK9#323934Spiral
• PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis#854416ClinicalTrials.gov
• PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)#877748ClinicalTrials.gov
• In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction#905445ClinicalTrials.gov
• Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study#908356ClinicalTrials.gov
• PCSK9 Inhibitor Treatment for Patients With SPG5#908477ClinicalTrials.gov
• A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)#914796ClinicalTrials.gov
• Effects of inclisiran therapy on metabolomic and lipoproteomic profiles in dyslipidemic patients#398940IRIS
• Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography#897993ClinicalTrials.gov
• Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer's disease models.#220899NCBI PubMed Central
• Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia#909856ClinicalTrials.gov
• Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients#810233ClinicalTrials.gov
• A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia#913191ClinicalTrials.gov
• Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody#895422ClinicalTrials.gov
• Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque#911037ClinicalTrials.gov
• PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer#180402ClinicalTrials.gov
• A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids#825596ClinicalTrials.gov
• Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes#994625ClinicalTrials.gov
• <b>Supporting data for</b><b> "</b><b>Piezoelectric Nanomedicine for Ultrasound-Activated Therapy of Hepatocellular Carcinoma" </b>#430034Figshare
• Efficacy and safety of PCSK9 inhibitors for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review and meta-analysis of randomised controlled trials#651095bioRxiv / medRxiv
• Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques#850244ClinicalTrials.gov
• Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism#909745ClinicalTrials.gov
• Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4#848063ClinicalTrials.gov
• Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C#804307ClinicalTrials.gov
• Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids#268576HAL (France)
• Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol#322568HAL (France)
• A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)#902904ClinicalTrials.gov
• Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment#859734ClinicalTrials.gov